Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00443443 · ClinicalTrials.gov registry record
A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)
A clinical trial, sponsored by Genentech.
- Completed
- Registry status
- 1,026
- Enrollment target
NCT00443443: Completed study, sponsored by Genentech.
NCT00443443 is a clinical trial that has completed, run by Genentech. The registered enrollment target is 1,026 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00443443 has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- 1,026 participants
- Enrollment target
Study Summary
This is an observational study designed to follow patients with RA who have had an inadequate response to one or more anti-TNF therapies and who will receive Rituxan. Approximately 1000 patients in the United States with RA who have had an inadequate response to anti-TNF therapies and who will receive Rituxan therapy will be recruited. There is no protocol mandated treatment assignment in this study. Patients will be evaluated and treated according to their physician's standard practice and discretion.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,026 participants |
| Start Date | 2007-01 |
| Est. Completion | 2013-09 |
What the finished NCT00443443 record still lists
NCT00443443 is an observational study that tracks outcomes without assigning an intervention. Its 1,026 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00443443 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00443443 about?
NCT00443443 is a clinical study titled "A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)". This is an observational study designed to follow patients with RA who have had an inadequate response to one or more anti-TNF therapies and who will receive Rituxan. Approximately 1000 patients in the United States with RA who have had an inadequate response to anti-TNF therapies and who will recei...
What is the current status of trial NCT00443443?
This trial is currently completed. The enrollment target is 1,026 participants. The study started on 2007-01. Estimated completion is 2013-09.
Who is sponsoring clinical trial NCT00443443?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02200276 · 1,025 participants · NA
Influenza Immunization in Adults Over Age 75
- NCT02296450 · 1,025 participants
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
- NCT06888011 · 1,024 participants · NA
iAmHealthy Clinical Practice Guideline (CPG)
- NCT07216703 · 1,023 participants · Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia